Objective: This study tested the effects of ketamine on vulnerability of female adolescent mice to activity-based anorexia (ABA).
| INTRODUCTION
There is at present no accepted pharmacological treatment for anorexia nervosa (AN) due, in part, to the limited knowledge of its etiology. Activity-based anorexia (ABA) is an animal model of AN that can provide clues regarding the neurobiological bases for vulnerability to AN. ABA captures four hallmarks of AN (American Psychiatric Association, 2013; Gutierrez, 2013) : (a) excessive voluntary exercise (Wable, Min, Chen, & Aoki, 2015) , (b) food restriction (FR), which appears to be voluntary, since animals continue to run on a wheel even during the hours of food availability (Chen, Wable, Chowdhury, & Aoki, 2016) , which yield (c) weight loss so severe as to be lethal, even though equivalent degree of FR without a wheel is not lethal, and (d) heightened anxiety after weight recovery. Hyperactivity is readily evoked upon~80% of wheel-acclimated wildtype adolescent female mice by restricting food access to 2 hr per day (Chowdhury, Chen, & Aoki, 2015; Chowdhury, Wable, Sabaliauskas, & Aoki, 2013) . Previously, we showed that FR elevated anxiety-like behavior that was measurable during the recovery period, even though body weight had been restored 5 days prior (Chen, Surgent, Rana, Lee, & Aoki, 2017) .
Moreover, an individual's vulnerability to FR-evoked wheel running activity is highly correlated with individual's anxiety-like behaviors (Wable et al., 2015) .
The dorsal and ventral hippocampus of adolescent females that have undergone ABA exhibit significant morphological and molecular changes (Aoki, Chowdhury, Wable, & Chen, 2017) . Ventral hippocampus is crucial for regulating anxiety responses (Bannerman et al., 2003; Jimenez et al., 2018) . However, previous studies indicate that the dorsal hippocampus is also important for anxiety regulation (Huttunen & Myers, 1986; Kataoka et al., 1991) , especially among adolescent females (Shen et al., 2007) . In the dorsal hippocampus, individuals' ABA vulnerability, based on weight loss, correlates with elevated levels of NR2B subunits of NMDA receptors at synapses (Chen, Actor-Engel, et al., 2017) . We reasoned that if elevation of NR2B-containing NMDARs are causal to ABA vulnerability, then blockade of NR2B-NMDARs may reduce ABA vulnerability. Ketamine is a non-competitive NMDAR antagonist, a single administration of which elicits fast and sustained antidepressant effects both in humans (Berman et al., 2000; Zarate et al., 2006) and animals (Autry et al., 2011; Li et al., 2010; Maeng et al., 2008; Zanos et al., 2016) , possibly through antagonism of the NR2B-NMDARs (Miller et al., 2014) . Ketamine is also anxiolytic in humans (aan het Rot et al., 2010; Krystal et al., 1994) and animals (Jiang et al., 2017) . Thus, we asked whether a single systemic injection of ketamine in mid-adolescence could reduce ABA vulnerability through its anxiolytic action.
| MATERIALS AND METHODS

| Animals
Twenty-four female C57Bl/6 J littermates in this study were bred at New York University's animal facility (Wable et al., 2015) . All procedures relating to the use of animals were in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals and approved by the IACUC of New York University (A3317-01). All animals were kept on a 12/12 light-dark cycle (lights on at 0700 h). Food and water were available ad libitum, except as noted below. After weaning at postnatal day (P) 25 (P25), animals of the same sex were group-housed 2-4 per cage ( Figure 1a ).
| ABA induction
ABA induction consisted of exposing wheel-acclimated singly-housed adolescent mice to two bouts of food restriction (FR)-the first and second ABA-with recovery in between (Figure 1a) , as was described previously (Chen et al., 2016; Chowdhury et al., 2013; Wable et al., 2015 ; see Supporting Information). On P42, animals were pseudorandomly assigned to one of three treatment groups-ketamine (3 and 30 mg/kg)-injected or vehicle (saline) controls, counter-balanced to ensure that the groups' average body weight and baseline running were not significantly different (Figure 1a 
| Elevated plus maze
Anxiety-like behaviors were measured by the elevated plus maze (EPM) test, conducted on P49 and P62 during the dark cycle. EPM duration was 10 min (Wable et al., 2015) . The time spent in the open arms was recorded and analyzed using the EthoVision tracking system (version X12, Noldus Information Technology, Wageningen, The Netherlands).
| Statistical analysis
Normality of the distribution of measures was tested using the D'Agostino & Pearson omnibus normality test, Shapiro-Wilk normality test, and Kruskal-Wallis test. One-way analysis of variance (ANOVA) was used to evaluate significance of the differences among the three treatment groups, followed by Fisher's least significant difference (LSD) post hoc analysis. Repeated measures two-way ANOVA was used to evaluate significance of the differences among the three treatment groups across days, followed by Fisher's LSD post hoc analysis.
All the results are expressed as mean AE SEM, with p-values <.05 considered statistically significant. GraphPad Prism Version 7.01 and IBM SPSS 24.0 were used.
| RESULTS
| Ketamine increases food intake during the first ABA in mid-adolescence
No difference in food consumption was detected among the groups prior to assignment of animals to the vehicle and two ketamine groups were significantly greater, compared to its food consumption on P41 (p = .008 and p = .0001, respectively). On P43, ketamine (3 mg/kg) also enhanced feeding marginally, compared to vehicle group (p = .051).
No difference among ketamine and vehicle groups was found in food intake during baseline (P36-40) or of weight loss or wheel running activity induced by FR during the first ABA (Supporting Information, Table S1 ).
| Ketamine facilitates weight gain during recovery that follows the first ABA
At the end of the first ABA on P44, comprised of 3 days of FR, no difference was found in weight loss among the three groups (vehicle group: −27.072% AE 1.635%; ketamine (3 and 30 mg/kg): −23.71% AE 1.516%, Table S1 ).
3.3 | Ketamine increases food intake and weight gain during the feeding hours of the second ABA 1 Single injection of ketamine increases food intake under FR during the first ABA and facilitates weight restoration during recovery and reduces anxiety-like behaviors panel a and b: Scheme of activity-based anorexia (ABA) design and timing of drug injections. All female C57Bl/6 J mice experienced repeated ABA exposures, the first ABA in mid-adolescence (P36-44) and the second one in late-adolescence (P51-59). On P42, the second day of the first ABA, female mice were assigned to either vehicle or ketamine groups that received vehicle or ketamine (3 and 30 mg/kg) injection at 6 p.m. 1 hr before the 2 hr of food access (7-9 p.m.). Anxiety-like behaviors were measured by the elevated plus maze (EPM) test, conducted on P49 and P62 panel c: ketamine (30 mg/kg) increases food intake under ABA during mid-adolescence. Before drug injection, on P41, no difference was found on food intake among three groups of animals that were assigned to the two groups (bars filled with stripes). On P42 and P43, the ketamine (30 mg/kg) group consumed more food compared to vehicle controls. * indicates p < .05. # indicates p = .05. $ indicates p < .05, compared to the food intake on P41 of the same group. Panel d: Ketamine (30 mg/kg) facilitates weight gain during recovery from ABA. After the end of the first ABA, repeated measures two-way ANOVA showed that the ketamine (30 mg/kg) group gained more weight during recovery period, especially on the last 3 days of recovery, P49-51. * indicates p < .05 revealed by Fisher's LSD test, comparing to the vehicle group. Panel e: ketamine (30 mg/kg) reduced anxiety-like behavior during recovery from the first ABA. Ketamine (30 mg/kg) group spent more time in the open arms. * indicates p < .05 p = .06, 23%; P57, p = .028, 24%; P58, p = .001, 38%). On the other hand, post hoc analysis revealed that lower dose of ketamine (3 mg/kg) had no effect on food intake compared to vehicle group (p = .5).
Weight gain during the 2 hr of food availability also differed among the three groups. Repeated measures two-way ANOVA of this measure revealed a marginally significant main effect of treatment (F [2,21] = 3.162, p = .06), and revealed by post hoc analysis that the ketamine (30 mg/kg) group gained more weight, compared to vehicle group (p = .02). On FR day 1 (P55), after 6 hr of FR, no difference was found in weight gain between the ketamine (30 mg/kg) injected and vehicle groups (Figure 2b , p = .81). On the last 2 days of FR, the ketamine (30 mg/kg) group showed more efficient weight gain during the feeding hours, compared to the vehicle controls (P57, p = .09, 20%; P58, p = .001, 47%). Post hoc analysis revealed that the lower dose of ketamine (3 mg/kg) had no effect on weight gain during 2 hr of food availability compared to vehicle group (p = .26).
3.4 | Ketamine attenuates food restriction-induced wheel running and weight loss during the second ABA FIGURE 2 Single injection of ketamine in mid-adolescence has enduring protective effects that are evident during the second ABA and recovery. Panels a and b: Single injection of ketamine (30 mg/kg) in mid-adolescence increases food intake (a) and weight gain (b) under second ABA exposure during late-adolescence. On the first day of FR during the second ABA (P55), no difference was found on food intake (a) or weight increase during the 2-hr feeding period (b) among the three groups. On the second (P56), third (P57), and last day (P58) of FR, the ketamine (30 mg/kg) group increased food intake and gained more weight during the 2-hr feeding period compared with the vehicle controls. * indicates p < .05, comparing to the vehicle group. # indicates p < .1, comparing to the vehicle group. Panel c and d: Single injection of ketamine in midadolescence attenuates FR-induced hyperactivity (c) and weight loss (d) under the second ABA exposure during late-adolescence. Ketamine (3 and 30 mg/kg) groups showed less averaged wheel running activity during 4 days of FR of the ABA, compared to vehicle controls. The ketamine (30 mg/kg) group also lost less weight at the end of the second ABA, compared with vehicle group. * indicates p < .05. # indicates p < . Table S1 ).
3.6 | Ketamine reduces anxiety-like behavior after recovery from the first and second ABA Previously, we showed that FR elevated anxiety-like behavior that was measurable during the recovery period, even though body weight had been restored 5 days prior (Chen, Surgent, Rana, Lee, & Aoki, 2017) . We investigated whether ketamine ameliorates this post-FR elevation of anxiety-like behavior. On P49, by which time animals' body weights were fully recovered from the first ABA, one-way ANOVA revealed significant main effect of treatment (F 
| DISCUSSION
Vulnerability of adolescent female mice to ABA can be quantified by (a) the FR-evoked heightened wheel running activity which (b) exacerbates weight loss (Chowdhury et al., 2013) , together with (c) the enduring effect of stress-induced anxiety-like behavior, evident among recovered animals with fully restored body weight (Chen, Surgent, et al., 2017) . We show that a single systemic ketamine (30 mg/ kg, i.p.) injection effectively attenuates all three of these measures of ABA vulnerability, in addition to promoting increased food intake immediately and for prolonged period (at least 16 days), ultimately contributing to the suppression of body weight loss during the second ABA. Although the weight loss effect was marginal (p = .056), it shows promise that perhaps multiple dosing of ketamine, such as another during the second ABA, would have yielded suppression that reached statistical significance. We also show that a single ketamine injection in mid-adolescence has long-lasting effects of suppressing FR-induced anxiety, evident 16 days later. Reduction of anxiety-like behavior by ketamine is already evident during the recovery phase from the first ABA, 7 days later. This may have contributed to the suppression of FR-induced hyperactivity throughout the second ABA. These findings add to another recent study showing that ketamine decreases anxiety-like levels in rats under chronic stress (Jiang et al., 2017) .
These multiple effects of ketamine are all promising features for enhancing resilience of individuals to recurrence of ABA.
This finding is consistent with prior studies (Sarrau, Jourdan, Dupuis-Soyris, & Verwaerde, 2007; Treece, Ritter, & Burns, 2000) reporting that ketamine and other NMDAR antagonists increase feeding behaviors but reveals additionally that ketamine increases food intake specifically under food restriction (FR), since ketamine did not alter food intake following just 6 hr of FR on the first day of ABA or during the recovery phase.
We do not know how ketamine exerts its prolonged protective effect against ABA but underlying mechanisms have been hypothesized for ketamine's prolonged effect as an antidepressant: the reduction of eukaryotic elongation factor (eEF2) phosphorylation and desuppression of the translation of brain-derived neurotrophic factor (BDNF) in the hippocampus (Autry et al., 2011; Kavalali & Monteggia, 2015) . Ketamine may have an addictive potential and is not free of 
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